Stock listing

OTC:SRNE Sorrento Therapeutics, Inc. Stock

Follow Sorrento Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:SRNE

$0.0004 USD +0.0001 (+33.3%)

Close on Nov 20, 2026

Past year -91.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.0001 – $0.0004 USDNov 20, 2026
Volume
441,967 sharesNov 20, 2026
Market cap
$220,512 USDAt the close on Nov 20, 2026 · price × 551.3M shares outstanding
52-week range
$0.0001 – $0.0100 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$64 USDMedian day 73,281 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Sorrento Therapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:SRNE · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0004+0.0001+33.3%$0.0003$0.0004$0.0001441,967
$0.0003-0.0002-40.0%$0.0005$0.0005$0.0003465,766
$0.0005+0.0002+66.7%$0.0004$0.0006$0.0003279,226
$0.00030.00000.0%$0.0006$0.0006$0.0003320,830
$0.00030.00000.0%$0.0003$0.0046$0.0003578,658
$0.00030.00000.0%$0.0003$0.0003$0.000369,285
$0.00030.00000.0%$0.0003$0.0004$0.0003168,407
$0.00030.00000.0%$0.0003$0.0004$0.00011,372,640
$0.00030.00000.0%$0.0003$0.0010$0.0003121,583
$0.00030.00000.0%$0.0003$0.0004$0.0003203,787
$0.00030.00000.0%$0.0003$0.0003$0.000351,182
$0.00030.00000.0%$0.0003$0.0003$0.0003217,568
$0.00030.00000.0%$0.0003$0.0003$0.000327,691
$0.00030.00000.0%$0.0003$0.0004$0.000316,472
$0.00030.00000.0%$0.0003$0.0005$0.0003234,692
$0.00030.00000.0%$0.0003$0.0050$0.000310,988
$0.0003-0.0004-57.1%$0.0003$0.0005$0.000317,723
$0.0007+0.0006+600.0%$0.0001$0.0007$0.0001403,304
$0.0001-0.0001-50.0%$0.0001$0.0002$0.000131,767
$0.0002+0.0001+100.0%$0.0002$0.0002$0.000172,025
$0.0001-0.0002-66.7%$0.0002$0.0010$0.000130,712
$0.0003+0.0001+50.0%$0.0001$0.0046$0.00018,917
$0.0002-0.0006-75.0%$0.0001$0.0020$0.000128,126
$0.0008+0.0006+300.0%$0.0002$0.0029$0.000257,250
$0.0002-0.0003-60.0%$0.0001$0.0002$0.000128,501
$0.00050.00000.0%$0.0005$0.0010$0.000529,020
$0.0005+0.0003+150.0%$0.0005$0.0010$0.000551,244
$0.0002-0.0001-33.3%$0.0001$0.0006$0.000146,016
$0.0003-0.0003-50.0%$0.0001$0.0006$0.000119,896
$0.0006-0.0002-25.0%$0.0008$0.0010$0.0001149,142
$0.00080.00000.0%$0.0008$0.0008$0.000888,510
$0.00080.00000.0%$0.0008$0.0010$0.000878,361
$0.00080.00000.0%$0.0008$0.0008$0.000839,275
$0.00080.00000.0%$0.0008$0.0008$0.0008180,129
$0.00080.00000.0%$0.0005$0.0008$0.0005143,522
$0.00080.00000.0%$0.0008$0.0008$0.000822,761
$0.00080.00000.0%$0.0008$0.0008$0.000892,792
$0.00080.00000.0%$0.0008$0.0010$0.000866,783
$0.00080.00000.0%$0.0008$0.0008$0.000835,101
$0.00080.00000.0%$0.0008$0.0008$0.000835,800
$0.00080.00000.0%$0.0008$0.0008$0.000813,898
$0.0008+0.0003+60.0%$0.0005$0.0009$0.000521,117
$0.00050.00000.0%$0.0005$0.0008$0.0005178,456
$0.00050.00000.0%$0.0004$0.0005$0.0004132,165
$0.0005+0.0002+66.7%$0.0001$0.0005$0.000165,381
$0.0003-0.0001-25.0%$0.0004$0.0008$0.0001116,109
$0.00040.00000.0%$0.0006$0.0006$0.000440,687
$0.00040.00000.0%$0.0004$0.0006$0.000479,548
$0.00040.00000.0%$0.0006$0.0006$0.000488,787
$0.00040.00000.0%$0.0006$0.0006$0.000464,522
$0.00040.00000.0%$0.0006$0.0006$0.000473,281
$0.0004-0.0001-20.0%$0.0004$0.0006$0.000433,800
$0.0005+0.0001+25.0%$0.0006$0.0006$0.000454,942
$0.0004-0.0002-33.3%$0.0005$0.0006$0.0004129,160
$0.00060.00000.0%$0.0090$0.0100$0.0006501,682
$0.00060.00000.0%$0.0001$0.0006$0.000126,035
$0.00060.00000.0%$0.0006$0.0011$0.000691,492
$0.00060.00000.0%$0.0006$0.0012$0.0006192,863
$0.0006+0.0001+20.0%$0.0009$0.0015$0.000688,266
$0.00050.00000.0%$0.0005$0.0006$0.000526,838
$0.00050.00000.0%$0.0005$0.0006$0.000526,750
$0.0005-0.0004-44.4%$0.0004$0.0013$0.0004103,292
$0.0009+0.0002+28.6%$0.0005$0.0010$0.0005135,982
$0.0007-0.0001-12.5%$0.0008$0.0014$0.0006332,415
$0.00080.00000.0%$0.0008$0.0013$0.000888,367
$0.00080.00000.0%$0.0008$0.0050$0.000839,050
$0.00080.00000.0%$0.0008$0.0008$0.0008166,464

Splits

3 splits since 2007 · OTC:SRNE · every price before a split is adjusted for it

DayRatioWhat
1-for-25Consolidation
1-for-10Consolidation
1-for-20Consolidation
Ticker
OTC:SRNE
Asset type
Stock
Exchange
OTC
Currency
USD

Sorrento Therapeutics, Inc. on 6ix

Decks
41 decks · latest Aug 1, 2023

Valuation

price Nov 20, 2026

Enterprise value
No statements on 6ix yet
P/E
No statements on 6ix yet
EV/sales
No statements on 6ix yet
EV/EBITDA
No statements on 6ix yet
Price/book
No statements on 6ix yet
Gross margin
No statements on 6ix yet
Operating margin
No statements on 6ix yet
Net margin
No statements on 6ix yet
Debt to equity
No statements on 6ix yet
Beta vs S&P 500
1.32

Team and board

Officers

OfficerRole
Henry JiChairman, President and CEO
John WaldheimExecutive Director, Government Affairs
Scott SchausChief Technology Officer

Board

DirectorRole
Henry JiChairman, President and CEO
John WaldheimExecutive Director, Government Affairs

Events

QuarterResultsShare move
Quarter to Dec 31, 2025Feb 25, 2026−31.3%
Quarter to Sep 30, 2025Nov 28, 2025−38.6%
Quarter to Jun 30, 2025Aug 29, 2025−16.7%
Quarter to Mar 31, 2025May 30, 2025−23.5%
Quarter to Dec 31, 2024Feb 26, 20250.0%
Quarter to Sep 30, 2024Nov 29, 2024−16.7%
Quarter to Jun 30, 2024Aug 13, 2024+23.1%
Quarter to Mar 31, 2024May 7, 2024−15.6%
Quarter to Dec 31, 2023Feb 28, 2024+1.1%
Quarter to Sep 30, 2023Nov 3, 2023+12.8%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 14, 2023+6.7%
Q1 2023May 15, 2023 · After close+3.1%
Q4 2022Mar 9, 2023−6.0%
Q3 2022Nov 8, 2022 · After close−4.1%
Q2 2022Aug 15, 2022 · After close−8.4%
Q1 2022May 5, 2022 · After close−5.0%
Q4 2021Mar 11, 2022 · After close−8.3%
Q3 2021Nov 5, 2021 · After close−0.7%
Q2 2021Aug 6, 2021 · After close+4.2%
Q1 2021May 5, 2021 · After close−4.2%

Open Events

Decks

DeckKindSlidesDate
Presentation (August 2023)9 slidesAug 1, 2023
SPAC Merger (March 2022)SPAC merger21 slidesMar 18, 2022
Technical Presentation (January 2022)Technical13 slidesJan 21, 2022
SPAC Merger (December 2021)SPAC merger57 slidesDec 13, 2021
Technical Presentation (November 2021)Technical9 slidesNov 29, 2021
Investor Presentation (September 2021)Investor deck37 slidesSep 13, 2021
Corporate Update (August 2021)Corporate update14 slidesAug 9, 2021
Investor Presentation (January 2021)Investor deck36 slidesJan 11, 2021
Investor Presentation (November 2020)Investor deck32 slidesNov 17, 2020
Investor Presentation (February 2020)Investor deck40 slidesFeb 27, 2020
All 41 decks
DeckKindSlidesDate
Investor Presentation (August 2019)Investor deck35 slidesAug 12, 2019
IPO Roadshow (June 2019)IPO roadshow36 slidesJun 28, 2019
Investor Presentation (June 2019)Investor deck25 slidesJun 20, 2019
Technical Presentation (June 2019)Technical26 slidesJun 19, 2019
Investor Presentation (May 2019)Investor deck27 slidesMay 21, 2019
Investor Presentation (April 2019)Investor deck18 slidesApr 16, 2019
Investor Presentation (April 2019)Investor deck27 slidesApr 15, 2019
Investor Presentation (December 2017)Investor deck29 slidesDecember 2017
Investor Presentation (September 2017)Investor deck29 slidesSeptember 2017
29th Annual ROTH Conference 2017Conference28 slidesMar 13, 2017
Investor Presentation (February 2017)Investor deck19 slidesFebruary 2017
Investor Presentation (November 2016)Investor deck17 slidesNovember 2016
Investor Presentation (September 2016)Investor deck41 slidesSep 22, 2016
Scintilla Pharmaceuticals — Investor Presentation (September 2016)Investor deck41 slidesSep 21, 2016
Investor Presentation (September 2016)Investor deck21 slidesSeptember 2016
Investor Presentation (January 2016)Investor deck52 slidesJanuary 2016
Investor Presentation (October 2015)Investor deck50 slidesOctober 2015
Investor Presentation (August 2015)Investor deck42 slidesAugust 2015
Investor Presentation (June 2015)Investor deck30 slidesJune 2015
Investor Presentation (February 2015)Investor deck34 slidesFeb 9, 2015
Investor Presentation (January 2015)Investor deck38 slidesJan 12, 2015
Investor Presentation (October 2014)Investor deck34 slidesOct 15, 2014
Investor Presentation (June 2014)Investor deck37 slidesJun 3, 2014
Investor Presentation (March 2014)Investor deck33 slidesMar 20, 2014
Investor Presentation (February 2014)Investor deck36 slidesFebruary 2014
Investor Presentation (December 2013)Investor deck36 slidesDecember 2013
Investor Presentation (November 2013)Investor deck37 slidesNov 19, 2013
Investor Presentation (October 2013)Investor deck34 slidesOct 4, 2013
Investor Presentation (October 2013)Investor deck34 slidesOctober 2013
Investor Presentation (September 2013)Investor deck29 slidesSep 11, 2013
Jefferies 2013 Global Healthcare ConferenceConference33 slidesJun 6, 2013

Open Decks

Financials

Annual, in USD

Income statement

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Revenue62.8M52.9M40.0M31.4M21.2M151.9M8.15M4.59M3.83M460.1K
Cost of revenue33.5M13.0M9.94M12.2M7.06M3.94M811.0K1.95M2.04M4.44K
Gross profit29.4M39.9M30.0M19.2M14.1M147.9M7.34M2.64M1.78M455.7K
Research and development221.2M206.9M111.3M106.9M77.0M55.5M42.2M31.3M24.0M9.02M
Selling, general and administrative182.3M196.9M116.2M103.6M63.6M38.3M24.2M20.1M9.99M6.32M
Operating income-378.5M-368.0M-201.5M-195.2M-150.4M25.3M-96.8M-74.0M-34.7M-21.7M
Depreciation and amortization13.2M12.5M11.0M11.0M9.05M7.08M2.88M2.37M3.18M1.29M
EBITDA-365.3M-355.6M-190.5M-184.2M-141.4M32.4M-93.9M-71.6M-31.6M-20.4M
Interest expense8.57M10.2M20.2M36.1M57.6M4.98M1.61M1.65M1.63M253.2K
Income before tax-561.7M-462.5M-310.6M-359.6M-213.8M15.3M-64.8M-13.8M-36.4M-21.9M
Income tax-2.42M-33.5M-2.01M-473.0K-6.27M-36.0M-896.0K36.3M-1.70M0
Net income-559.3M-429.0M-308.6M-359.1M-203.5M9.13M-60.9M-45.8M-34.7M-21.9M
Earnings per share, basic-1.33-1.46-1.34-2.56-1.920.13-1.21-1.24-1.30-1.46

Balance sheet

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash and equivalents23.6M36.7M56.5M22.5M158.7M20.4M82.4M39.0M71.9M31.7M
Short-term investments26.3M90.2M256.4M297.0K441.0K1.11M97.4M00
Receivables24.5M18.7M15.5M14.5M4.36M3.93M2.98M2.62M732.0K394.2K
Inventory9.98M8.11M1.83M3.36M2.90M00000
Current assets96.4M173.0M86.2M67.6M179.6M29.7M89.7M141.0M73.9M32.6M
Property, plant and equipment52.0M41.3M31.9M29.9M24.4M19.3M12.7M7.25M2.28M2.44M
Goodwill80.3M79.5M43.6M38.3M38.3M38.3M41.5M20.6M24.0M24.0M
Total assets472.8M694.8M535.8M557.6M624.1M431.6M401.6M343.5M141.5M92.6M
Accounts payable47.5M27.4M24.7M27.6M13.8M9.91M8.28M1.34M1.66M2.15M
Current liabilities327.9M139.5M96.5M115.2M61.6M79.0M76.1M30.9M9.56M5.48M
Long-term debt19.1M110.6M92.3M199.1M223.1M5.21M47.1M4.39M8.83M4.43M
Total debt134.5M237.6M169.4M290.8M233.3M5.21M47.3M9.23M12.1M4.80M
Total liabilities494.5M616.7M395.1M524.9M416.6M225.0M315.1M202.6M32.8M25.8M
Shareholders' equity-21.7M78.1M140.7M32.8M207.5M206.6M86.5M140.9M108.7M66.8M
Shares outstanding419.3M294.8M229.8M140.5M106.2M70.4M50.4M36.9M26.7M15.0M

Cash flow

LineFY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015FY2014FY2013
Cash from operations-293.9M-281.8M-159.5M-173.0M-111.8M-99.2M-70.9M-42.1M-28.8M-16.5M
Capital spending-13.7M-8.87M-37.6M-11.4M-11.2M-11.0M-6.86M-3.71M-591.0K-931.3K
Free cash flow-307.5M-290.7M-197.1M-184.4M-123.0M-110.2M-77.8M-45.8M-29.4M-17.4M
Cash from investing-28.5M79.8M-39.9M-38.2M-21.2M-16.5M-17.5M12.6M-10.6M-503.5K
Cash from financing311.7M181.3M174.2M78.9M326.0M53.7M131.7M-3.35M79.6M43.6M
Dividends paid00000
Share buybacks403.5M217.2M-55.0M56.5M61.4M57.9M-15.6M1.75M72.1M37.7M
Change in cash-13.0M-19.8M-24.3M-132.6M192.9M-62.0M43.4M-32.9M40.2M26.6M

Open Financials

Cap table

Built by 6ix from Sorrento Therapeutics, Inc.’s releases

Common shares
551,281,154
Fully diluted
551,281,154

Fully diluted

LineShares
Common shares551,281,154

Share count over time

CountShares
Nov 22, 2026551,281,154

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Huntington National Bank5,000<0.01%US$4Sep 30, 2026
Oakworth Capital, Inc.350<0.01%Sep 30, 2026
Financial Gravity Asset Management, Inc.18<0.01%Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Jane Hsiao
Other companies: OPKO Health, Inc. (Vice Chairman and Chief Technical Officer · Since at least Feb 9, 2007); Cocrystal Pharma, Inc. (Director · Mar 17, 2014 – Sep 21, 2018 · Past); PROLOR Biotech Inc (Director · Jul 23, 2009 – Aug 29, 2013 · Past); Non-Invasive Monitoring Systems, Inc. (Interim CEO, Director · Oct 30, 2008 – Dec 21, 2018 · Past); Asensus Surgical Inc (Director · Aug 24, 2007 – Jun 30, 2021 · Past); Protalix BioTherapeutics, Inc. (de) (Director · Dec 31, 2006 – Jan 31, 2007 · Past); Ivax Corp (Vice Chairman and CTO, Director · Jan 26, 2006 – Jan 26, 2006 · Past)
Director · Jan 25, 2010 – Feb 6, 2012 · Past
Jerome Zeldis
Other companies: NexGel, Inc (Director · Since at least Mar 8, 2021); PTC Therapeutics, Inc. (Director · Since at least Jun 19, 2013); Soligenix, Inc. (Board Director · Since at least Jun 22, 2011); NexImmune, Inc. (Executive VP of Research & Dev · Feb 11, 2021 – Apr 5, 2022 · Past); MetaStat Inc (Director · Oct 11, 2017 – Oct 11, 2017 · Past); Beyond Air, Inc. (Director · Mar 14, 2017 – Mar 14, 2017 · Past); Streamex Corp. (Director · Jul 20, 2015 – Jul 14, 2020 · Past)
See Remarks · Aug 12, 2016 – Nov 26, 2018 · Past
Robin L. Smith
Other companies: Matinas BioPharma Holdings, Inc. (Director · Feb 13, 2025 – Nov 4, 2026 · Past); Cycurion, Inc. (Director · Jan 11, 2022 – Jan 11, 2022 · Past); Celularity Inc. (Director · Jul 16, 2021 – Jun 14, 2023 · Past); ServiceSource International Inc (Director · Feb 27, 2020 – May 20, 2020 · Past); Rockwell Medical, Inc. (Director · Jun 6, 2019 – Jun 6, 2019 · Past); Emmaus Life Sciences, Inc. (Director · May 8, 2019 – May 8, 2019 · Past)
Director · Dec 16, 2019 – Sep 3, 2021 · Past
Glenn L Halpryn
Other companies: Niagen Bioscience, Inc. (Director · May 20, 2010 – Jul 6, 2015 · Past); Olenox Industries Inc. (Director · Apr 23, 2010 – Apr 23, 2010 · Past); Fluent, Inc. (Director · Oct 30, 2009 – Jan 11, 2010 · Past); Castle Brands Inc (Director · Oct 11, 2008 – Mar 26, 2015 · Past); BioCardia, Inc. (CEO, Director · Oct 30, 2007 – Aug 29, 2008 · Past)
Director · Feb 5, 2010 – Feb 6, 2012 · Past
Elizabeth Czerepak
Other companies: TransCode Therapeutics, Inc. (CFO, Director · Since at least Oct 6, 2025); Delcath Systems, Inc. (DIRECTOR · Since at least Feb 14, 2020); Scilex Holding Company (See Remarks · Nov 10, 2022 – Jan 17, 2023 · Past); Spectrum Pharmaceuticals Inc (Director · Jun 19, 2019 – Jun 18, 2020 · Past)
EVP & Chief Financial Officer · Nov 15, 2021 – May 18, 2022 · Past
Jaisim Shah
Other companies: Semnur Pharmaceuticals, Inc. (See Remarks, Director · Since at least Sep 22, 2025); Scilex Holding Company (See Remarks, Director · Nov 10, 2022 – Dec 18, 2024 · Past); Facet Biotech Corp (SVP, Chief Business Officer · Dec 9, 2008 – Dec 9, 2008 · Past); PDL BioPharma Inc (SVP, Mktg & Bus. Affairs · Jan 9, 2006 – Apr 28, 2008 · Past)
Director · Sep 9, 2013 – Aug 30, 2021 · Past
Miranda Toledano
Other companies: Entera Bio Ltd. (Chief Executive Officer and Board Member · Since at least Jan 1, 2022); Journey Medical Corporation (Director · Since at least Nov 16, 2021); NexGel, Inc (Director · Sep 9, 2021 – Aug 17, 2023 · Past); Compass Therapeutics, Inc. (Director · Jun 25, 2021 – Jun 25, 2021 · Past)
EVP-Corporate Development · Sep 16, 2016 – Sep 16, 2016 · Past
David Deming
Other companies: Phio Pharmaceuticals Corp. (Director · Since at least Feb 19, 2025); Better for You Wellness Inc. (Director · Since at least Sep 30, 2021); Albany Molecular Research Inc (Director · Jun 15, 2016 – Aug 31, 2017 · Past)
Director · Jul 11, 2016 – Sep 15, 2017 · Past
Edgar Lee
Other companies: Oaktree Specialty Lending Corporation (See Remarks · Oct 17, 2017 – Dec 15, 2017 · Past); Oaktree Strategic Income Corporation (See Remarks · Oct 17, 2017 – Dec 15, 2017 · Past); Charter Communications, Inc. (Director · Jan 18, 2011 – May 1, 2013 · Past)
Director · Dec 9, 2019 – Jun 15, 2020 · Past
Antonius Schuh
Other companies: Cardiff Oncology, Inc. (CEO, Director · Jan 23, 2012 – Jan 4, 2016 · Past); Precipio, Inc. (Director · May 20, 2009 – Feb 18, 2014 · Past)
Chairman and CEO, Director · Feb 16, 2010 – Feb 16, 2010 · Past
All 24 people
PersonSeat
Henry Ji
Other companies: Semnur Pharmaceuticals, Inc. (Executive Chairman, Chief Executive Officer and President · Since at least Nov 5, 2026); Scilex Holding Company (Executive Chairman, Chief Executive Officer and President · Since at least Jan 30, 2026)
Chairman, President and CEO · Since at least Nov 5, 2026
William S Marth
Other companies: Teligent Inc (Director · Feb 15, 2021 – Jul 21, 2021 · Past); Albany Molecular Research Inc (President and CEO, Director · Dec 31, 2015 – Aug 31, 2017 · Past)
Director · Jul 11, 2016 – Jul 11, 2016 · Past
Yue Alexander Wu
Other companies: Semnur Pharmaceuticals, Inc. (Director · Since at least Sep 22, 2025); Scilex Holding Company (Director · Since at least Sep 22, 2023)
Director · Aug 1, 2016 – Aug 30, 2021 · Past
Daniel J Levitt
Other companies: Neurogene Inc. (Director · Mar 6, 2014 – May 14, 2018 · Past)
Director · Jan 30, 2014 – Jan 30, 2014 · Past
Mark Durand
Other companies: Radius Health, Inc. (Chief Commercial Officer · Apr 1, 2014 – Jun 5, 2014 · Past)
EVP & CFO · Mar 7, 2014 – Apr 29, 2015 · Past
Michael Scott Salka
Other companies: Armata Pharmaceuticals, Inc. (Chief Executive Officer, Director · Aug 5, 2015 – Apr 1, 2017 · Past)
Director · Feb 23, 2012 – Jan 23, 2014 · Past
Steve Zaniboni
Other companies: Cardiff Oncology, Inc. (Former CFO · Jan 23, 2012 – Apr 21, 2016 · Past)
Director · Nov 29, 2010 – Nov 29, 2010 · Past
David Ritchie WebbDirector · Sep 6, 2012 – Oct 29, 2013 · Past
Dean FerrignoChief Accounting Officer · May 15, 2017 – Feb 28, 2018 · Past
Diane D S Tang-LiuDirector · Feb 23, 2012 – Jul 20, 2012 · Past
Douglas O EbersoleDirector · Aug 6, 2014 – Jul 11, 2016 · Past
John WaldheimExecutive Director, Government Affairs · Since at least Nov 5, 2026
Scott SchausChief Technology Officer · Since at least Nov 5, 2026
Tammy ReillyDirector · May 18, 2022 – May 18, 2022 · Past

Open People

Log in to ask 6ix AI your own questions about Sorrento Therapeutics, Inc.